Company intelligence / Profile preview

Fujita Pharmaceutical

Ownership: Private
Employees: ~115
Development stage: Other

Overview

Fujita Pharmaceutical was a leading Japanese manufacturer of veterinary pharmaceuticals for both companion animals and livestock. Its products included heartworm preventives, anti-inflammatories, skin disease treatments for pets, and reproductive hormones for livestock. The company had a strong domestic presence with top market share in generic animal drugs. As of April 2024, it became part of Sasaeah under Virbac following acquisition.

Therapeutic areas: DermatologyRheumatologyEndocrinologyInfectious Diseases
Modalities: Small moleculeBiologic
Industry: Veterinary

Partnerships

OEM manufacturing partnerships with other pharmaceutical companies within Japan and export partners overseas

Beyond the preview

Go deeper on Fujita Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fujita Pharmaceutical.

Explore the full profile